# Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)

> **NCT01448239** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 24 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** alirocumab SAR236553 (REGN727)
- **DRUG:** alirocumab SAR236553 (REGN727)

## Key facts

- **NCT ID:** NCT01448239
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2013-06-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01448239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01448239, "Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01448239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*